CYTO-PV Trial Insights: Optimizing Hematocrit Targets - Targeted Oncology

Key claim: In polycythemia vera, both hematocrit control and white blood cell cytoreduction should be treated as independent therapeutic goals to reduce thrombotic risk, per CYTO-PV trial insights.

Abstract

Expert panel discussion highlighted findings supporting comprehensive polycythemia vera management addressing both hematocrit control and cytoreduction of white blood cells as independent goals to reduce thrombotic risk.

Why this matters

Pending synthesis.

Source

Link